carlos alvarez tirzepatide Fuente: Martin, C.K., Carmichael, O.T., Carnell, S. et al. on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med (2025) #drmauinforma Carlos Alvarez Peptide Reconstitution |

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity

Boise Biologics offers the latest in weight loss therapy

Losing weight is challenging but achievable

PlexusDx explains practical, clinically-backed methods to reduce gastrointestinal side effects while maintaining your weight loss momentum

Est indicado como complemento de la dieta y el ejercicio para mejorar el control glucmico en adultos con diabetes mellitus tipo 2, especialmente cuando otros tratamientos como la metformina son insuficientes o no son adecuados